BOOM

Trending Searches

    SUPPORT
    BOOM

    Trending News

      • Fact Check 
        • Fast Check
        • Politics
        • Business
        • Entertainment
        • Social
        • Sports
        • World
      • Law
      • Explainers
      • News 
        • All News
      • Decode 
        • Impact
        • Scamcheck
        • Life
        • Voices
      • Media Buddhi 
        • Digital Buddhi
        • Senior Citizens
        • Videos
      • Web Stories
      • BOOM Research
      • BOOM Labs
      • Deepfake Tracker
      • Videos 
        • Facts Neeti
      • Home-icon
        Home
      • About Us-icon
        About Us
      • Authors-icon
        Authors
      • Team-icon
        Team
      • Careers-icon
        Careers
      • Internship-icon
        Internship
      • Contact Us-icon
        Contact Us
      • Methodology-icon
        Methodology
      • Correction Policy-icon
        Correction Policy
      • Non-Partnership Policy-icon
        Non-Partnership Policy
      • Cookie Policy-icon
        Cookie Policy
      • Grievance Redressal-icon
        Grievance Redressal
      • Republishing Guidelines-icon
        Republishing Guidelines
      • Fact Check-icon
        Fact Check
        Fast Check
        Politics
        Business
        Entertainment
        Social
        Sports
        World
      • Law-icon
        Law
      • Explainers-icon
        Explainers
      • News-icon
        News
        All News
      • Decode-icon
        Decode
        Impact
        Scamcheck
        Life
        Voices
      • Media Buddhi-icon
        Media Buddhi
        Digital Buddhi
        Senior Citizens
        Videos
      • Web Stories-icon
        Web Stories
      • BOOM Research-icon
        BOOM Research
      • BOOM Labs-icon
        BOOM Labs
      • Deepfake Tracker-icon
        Deepfake Tracker
      • Videos-icon
        Videos
        Facts Neeti
      Trending Tags
      TRENDING
      • #Operation Sindoor
      • #Pahalgam Terror Attack
      • #Narendra Modi
      • #Rahul Gandhi
      • #Waqf Amendment Bill
      • #Arvind Kejriwal
      • #Deepfake
      • #Artificial Intelligence
      • Home
      • Coronavirus
      • Sputnik V Receives Emergency...
      Coronavirus

      Sputnik V Receives Emergency Approval, Other Vaccines To Follow

      The Russian vaccine will be manufactured by Dt. Reddy's Laboratories while other foreign manufacturers will have to conduct bridging studies

      By - Shachi Sutaria |
      Published -  13 April 2021 6:32 PM IST
    • Boomlive
      Sputnik V Receives Emergency Approval, Other Vaccines To Follow

      The National Expert Group on Vaccine Administration for COVID-19 on Tuesday announced that the Centre will fast-track emergency approvals for foreign COVID-19 vaccines that have already received approval by medical regulators along with WHO. This announcement came on the day India announced its third approved COVID-19 vaccine.

      The Drugs Controller General of India (DCGI) approved Sputnik V, produced by Russia's Gamaleya National Research Institute of Epidemiology and Microbiology for emergency use authorization (EUA) in India on Tuesday making it the third vaccine to receive EUA. This vaccine will be manufactured by Dr. Reddy's Laboratories from Hyderabad, who approached the DCGI to manufacture and distribute the vaccine in the country.

      Sputnik Vaccine Approval

      Found to have a 91.6% efficacy against SARS-CoV-2, the vaccine funded by the Russian Direct Investment Fund (RDIF) received a lot of criticism when the country approved the vaccine even when its Phase III trials were underway.

      Also Read:Russia's Announcement Of COVID-19 Vaccine Met With Scepticism

      The vaccine instead of using one vector uses two different adenoviral vectors for both the vaccine dosages. Just like AstraZeneca uses an adenoviral vector that causes common colds among humans, Sputnik scientifically known as Gam-COVID-Vac combined vector vaccine uses two of them.

      While the first vector (rAd26-) is administered through the first shot, the second vector (rAd25-) is given through the second dose after 21 days. According to the RDIF, the vaccine uses two different vectors to boost the immune response as well as reduces the risk of the immune system developing resistance to the initial vector. The vaccine has to be stored at -18°C in its liquid form and between 2-8°C if freeze-dried, thus not requiring any additional cold-chain infrastructure if kept refrigerated.

      Dr. Reddy's conducted Phase III trials across the country to check the safety and immunogenicity of the vaccine. Comparing the interim results of the Phase III results submitted by the manufacturer with the results of the clinical trials in Russia, the Subject Expert Committee comprising of pulmonologists, immunologists, microbiologists, pharmacologists, and others approved the vaccine for restricted emergency use authorization in the country.

      Along with Dr. Reddy's, five other pharmaceutical companies will also be manufacturing the vaccine according to deals signed with the RDIF. They are Gland Pharma, Hetero Biopharma, Virchow Biotech, Panacea Biotec and Stelis Biopharma. All of these manufacturers together will be able to produce 600 million doses in a year.

      This is the third vaccine to be approved by the DCGI along with Covishield and Covaxin but has the highest efficacy rate from all three. The government is yet to release the standard operating procedure for the distribution of Sputnik, its price, and also how many doses it plans to procure. So far, there have been no reports of adverse events linked to this vaccine.

      The Russian vaccine has so far been approved in 55 countries and RDIF plans to sell it at less than $10 per shot.

      Other Foreign Vaccines To Follow

      Other vaccines that have received emergency approval for restricted use are the ones approved by USFDA (US), EMA (EU), UK MHRA, PMDA Japan or which are listed in WHO (Emergency Use Listing). Instead of conducting large scale clinical trials, they will conduct post approval parallel bridging studies in which they will check if the results in India are similar to results in other countries. The bridging studies which are equivalent to Phase II/III will be conducted once the vaccines are approved.

      Furthermore, before starting large scale vaccination, the first 100 beneficiaries will be observed for seven days to assess if there are any adverse effects.

      This implies that COVID-19 vaccines manufactured by Pfizer, Johnson & Johnson, and Moderna could be fast-tracked if they decide to approach the DCGI for approval. When asked if the Chinese vaccines would be a part of the provisions, Health Secretary Mr. Rajesh Bhushan stated that all vaccines which are approved by either US, EU, UK, or Japan will be included in these trials.

      Also Read:India Needs 10 Mn COVID Vaccine Doses Daily, Producing Less Than Half


      Tags

      Sputnik V VaccinedcgicdscoCOVID-19
      Read Full Article
      Next Story
      Our website is made possible by displaying online advertisements to our visitors.
      Please consider supporting us by disabling your ad blocker. Please reload after ad blocker is disabled.
      X

      Subscribe to BOOM Newsletters

      👉 No spam, no paywall — but verified insights.

      Please enter a Email Address
      Subscribe for free!

      Stay Ahead of Misinformation!

      Please enter a Email Address
      Subscribe Now🛡️ 100% Privacy Protected | No Spam, Just Facts
      By subscribing, you agree with the Terms & conditions and Privacy Policy connected to the offer

      Thank you for subscribing!

      You’re now part of the BOOM community.

      Or, Subscribe to receive latest news via email
      Subscribed Successfully...
      Copy HTMLHTML is copied!
      There's no data to copy!